Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects

CONTEXT: Velcalcetide, also known as AMG 416, is a novel, long-acting selective peptide agonist of the calcium sensing receptor. It is being developed as an intravenous treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney disease—mineral and bone disorder. O...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Kevin J., Bell, Gregory, Pickthorn, Karen, Huang, Saling, Vick, Andrew, Hodsman, Peter, Peacock, Munro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910343/
https://www.ncbi.nlm.nih.gov/pubmed/24235081
http://dx.doi.org/10.1093/ndt/gft417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910343/
https://www.ncbi.nlm.nih.gov/pubmed/24235081
http://dx.doi.org/10.1093/ndt/gft417

Ejemplares similares